16 ways to position Oleo as Ireland's pre-Allwright cannabis monopoly. Refreshed against Wave A intel: full audit, AI deep audit, mega competitor table, 4 patient + 3 prescriber personas, founder credibility, 16-node business map, platform footprint, 63 OOB ideas. Every wedge is his to keep either way.
Internal Onlyv2 - Wave A refreshWhy this Vault exists. Tuesday 13 May is the Budtender discovery call. Oleo is the back-pocket "by the way" wow at the end. If Tomas + John + Donal see all 16 options before Tuesday, they can pick the angle that fits Richard's actual mood in the room, hybridise on the spot, or hold the deeper assets back for the Tue 20 May close. Every wedge here is engineered to leave Richard with something useful regardless of whether he signs. Wave A intel sharpens every score: we now have the 200-cell AI citation matrix, 4 patient personas with real Reddit verbatims, 7 named Irish journalists with verified mastheads, and 16 mapped business-family nodes that show why the cross-property cascade is real and not aspirational.
A pre-built launch sequence: 10 expansion-ready pages, full JSON-LD schema layer (Organization, MedicalBusiness, MedicalProcedure, Article, FAQPage, HowTo, Drug), the 22-consultant prescriber re-activation map, an OleoCare app-listing audit, and a post-Allwright oleo.ie mockup shipped inside 7 days so Oleo is the first MCAP supplier ranked, cited, and prescribed-from on the morning eligibility expands. Includes the 15-minute /about 301 fix and the Bedrocan provenance microsite folded into the schema spine.
"Day 1 of MCAP-expansion launch sequence prebuilt. Whether you sign with us or not, we would rather you have this ready before Allwright reports out."
Allwright is the only event Richard cannot ignore. Every other wedge is a branch off W1. The Readiness Package compresses 4 months of agency work into 7 days, lands on the operational bottleneck Richard already lives in (74 patients ever, 22 historic consultants, 70 percent stop after one script), and demonstrates regulatory plus AI-ranking plus ops fluency in a single package. Free-and-his-to-keep removes commitment pressure during what is structurally a bonus conversation. The 22-consultant map alone is an asset only an Irish-MCAP-aware agency can produce. The Bedrocan microsite alone fixes the most under-leveraged trust signal Oleo owns. The Allwright submission landing page (W3) inside it claims uncontested AI citation slots that the deep audit measured at 0 across all four engines today. The post-Allwright mockup is the close picture Richard holds for 30 days.
Each wedge scored on Wow Factor, Allwright leverage, and ASAI safety, each /5, total /20. Wave A intel re-scored every row. Cost is OO build cost. Time is calendar days from green-light to deliver. "His to keep" reflects whether the asset has standalone value if Richard does not sign a retainer.
| # | Wedge name | Cost to OO | Time | Wow /5 | Allwright /5 | ASAI /5 | His to keep | Total /20 |
|---|---|---|---|---|---|---|---|---|
| W1 | Oleo Regulatory Readiness Package Locked 10 pages + JSON-LD + 22-consultant map + OleoCare audit + post-Allwright mockup + Bedrocan microsite + /about 301 |
Free | 7 days | 5 | 5 | 5 | Yes - full | 20 |
| W2 | 22-Consultant Re-Activation Map (Pre + Post Allwright) Names, hospitals, specialties, last-known volume, tailored re-engagement asset per consultant |
Free | 3 days | 5 | 5 | 4 | Yes | 14 |
| W3 | Allwright Submission Landing Page + evidence pack Public dated submission page, patient outcomes, supply readiness, AI ranks at 1 today, lifts to 6 in 2-3 days |
Free | 4 days | 4 | 5 | 5 | Yes | 14 |
| W4 | Patient Navigator Pages per condition 5 condition pages (MS spasticity, intractable epilepsy, chemo nausea, refractory paediatric epilepsy, palliative holding) live in 7 days |
Free | 7 days | 4 | 3 | 5 | Yes | 12 |
| W5 | Bedrocan Trust Page + Provenance Microsite Fixes the orphaned moat: cultivation + GMP + cold-chain into Cork, schema.org partnerOf, NL magistral pipeline diagrammed |
Free | 3 days | 4 | 4 | 5 | Yes | 13 |
| W6 | Medical Cannabis ID Card brand-claim Free wallet credential for every patient. The orphaned brand asset Oleo can claim before any other supplier notices |
under EUR 1k | 6 days | 5 | 3 | 5 | Yes | 13 |
| W7 | HPRA Pharmacovigilance AI prototype Watches OleoCare side-effect reports, pre-fills HPRA quarterly returns, removes ops headcount as the constraint |
under EUR 1k | 10 days | 5 | 3 | 5 | Yes | 13 |
| W8 | Curaleaf Belfast vs Oleo NI-leak comparison Active legal frame: Belfast prescribes legally to NI residents, ROI cross-border transport is a Misuse of Drugs offence today |
Free | 3 days | 4 | 4 | 5 | Yes | 13 |
| W9 | Press Kit + Media Briefing (8 named journalists) Verified mastheads: Martin Wall, Catherine Shanahan, Catherine Reilly, Damien O'Reilly, Daniel McConnell, Niamh Cahill, Jane O'Faherty, Kelly-Jo Eastwood |
Free | 4 days | 4 | 4 | 5 | Yes | 13 |
| W10 | CME-CPD Accredited Content Series Issue 1 Module 1 of 6 shipped, RCPI / CPD-Ireland accreditation route opened. Travels through CPD infrastructure consultants log to. |
EUR 1-5k | 14 days | 4 | 4 | 5 | Yes | 13 |
| W11 | Stocking-Pharmacy Locator + Stock API skeleton Public locator + backend ordering UX, IPU-aligned, replaces email + phone supply chain when volume scales |
under EUR 1k | 8 days | 4 | 3 | 5 | Yes | 12 |
| W12 | truMED Provider+Patient Bot Pattern Demo truPRO + truME architecture ported into MCAP context. FHIR-compliant export 80%+ overlap with HPRA pharmacovigilance shapes. |
under EUR 1k | 6 days | 5 | 3 | 4 | Partial | 12 |
| W13 | 5-Outlet Pre-Pitch Package (ready-to-send) Catherine Reilly (IMT + Medical Independent dual path) + Catherine Shanahan + Martin Wall + Damien O'Reilly + Daniel McConnell. Subject lines + opening paragraphs drafted. |
Free | 2 days | 4 | 4 | 5 | Yes | 13 |
| W14 | Olio.com Waitlist Entity Layer + Wikidata Q-item Holding-page founder paragraph, /perspective bylines, schema.org sameAs entity graph. Adds a 3rd anchor to Wikipedia notability. |
Free | 5 days | 3 | 3 | 5 | Yes | 11 |
| W15 | AI-Citation Live Scoreboard 200-cell matrix retest at weeks 4 + 12 + 24, Allwright Review query at the centre. Lifts from 11 percent floor to 19-23 percent. |
under EUR 1k | 5 days | 5 | 3 | 5 | Yes | 13 |
| W16 | Oireachtas Health Committee Briefing Pack 4-page exec summary + 12-page evidence appendix + 1-page Oleo positioning + meeting-request letter template. Only Irish MCAP voice producing one. |
Free | 5 days | 4 | 5 | 5 | Yes | 14 |
Note on scoring. W1 totals 20/20 because it bundles the highest-leverage individual wedges (W2 + W3 + W4 + W5 + post-Allwright mockup + ASO audit) into one shippable package and ships in 7 days. W2, W16 score 14: standalone, free, ship in 3-5 days, every Wave A doc points back to them. W3, W5, W6, W7, W8, W9, W10, W13, W15 cluster at 13: each is a single-shot wedge with one specific room-temperature it wins in. Anything below 12 is a hold-back for Phase 2, not a wedge entry point.
It is the single sharpest asset on the list (score 14, the highest non-locked). We do not lead with it because the map without the post-Allwright mockup is a recruitment tool, not a strategy. What would change our mind: if Richard says he is budget-constrained pre-Allwright, this is free, ships in 3 days, and stands alone. Right scenario: the Tue 20 May close call if he balks at scope. Also the right "starter" wedge to deploy in week 1 if W1 scope feels heavy.
AI deep audit ranks Allwright Review queries at 0 across all 4 engines today. A single dated submission page lifts that to 6 cells in 2-3 days. Strong on lobbying voice, weaker on operational signal alone. What would change our mind: if Richard mentions the Allwright submission directly on Tuesday. Right scenario: when he says "I am submitting to Allwright next month" the 48-hour W3 build is the right reply.
Mechanically necessary, strategically thin on its own. Folds inside W1 as the condition pages. Standalone it lacks the prescriber-side punch. The personas-v1.md cross-persona pattern says the consultant is the pivot for patients 1-3, the GP is the pivot for patient 4 post-Allwright. Patient pages alone do not move that needle. What would change our mind: if Richard names "patients can't find us" as the headline pain. Right scenario: the patient-stack hybrid (see below).
Lovely supporting asset. The credential that lifts every other credential by 2x, per founder-credibility-deep-dive.md section 6. The reason it is not the headline wedge: Bedrocan trust is implicit not explicit. Folding it inside W1's schema layer is more leveraged than shipping it alone. What would change our mind: if Richard frames Bedrocan supply as the pitch directly. Right scenario: sub-section inside W1 that takes 3 days of the 7-day build.
Brand-orphaned in Irish patient-advocacy circles, no supplier owns it. High wow on call (free wallet credential for every patient), lower Allwright leverage. ASAI permits patient-ID framing where it does not permit prescription-product framing. What would change our mind: if patient-discovery is named as the bottleneck (it usually is not, prescribers are). Right scenario: Phase 2, paired with Curaleaf comparison page (W8) and patient navigator (W4).
Highest operational wow factor in the list. Reason it is not lead: it takes 10 days, and Richard wants the launch sequence first. Hypothesised IIOP voice in personas-v1.md says "I am the pharmacovigilance bottleneck and nobody trained me", which W7 answers directly. What would change our mind: if Richard or Shirley names ops headcount as the constraint. Right scenario: The Operational Stack hybrid, or Phase 1 month 1.
Captures NI-to-ROI cross-border leak. Real demand signal: Belfast prescribes legally to NI residents, ROI cross-border transport is a Misuse of Drugs offence today. The cleanest evidentiary argument for Allwright expansion. What would change our mind: if Richard mentions UK clinics or Belfast specifically. Right scenario: sits inside the patient stack hybrid as a rank-trap for cross-border searches and as supporting evidence in the W16 Oireachtas pack.
Free PR is hard to refuse. 8 named Irish journalists with verified mastheads ready to receive. Less novel than the regulatory readiness frame because Richard already runs press through truMED. What would change our mind: if he mentions a specific journalist or pending media beat. Right scenario: the Pre-Allwright Stack hybrid, paired with W3 and W16. Catherine Reilly is the dual-path slot (IMT + Medical Independent both run her byline).
The most durable prescriber-education asset Oleo can own (oob-ideas-catalogue.md idea 27). Travels through CPD infrastructure consultants already log to. Reason it is not lead: 14 days build + accreditation process + EUR 1-5k cost is heavier than the 7-day free package. What would change our mind: if Richard expresses worry about prescriber education quality. Right scenario: The Prescriber Stack hybrid as Phase 2 retainer deliverable.
Beautiful long-term asset, premature today. With ~6-8 stocking pharmacies the locator is too thin to demo well, and platform-footprint-research.md confirms McLernons + United Drug exclude cannabis-based products from standard wholesale. What would change our mind: post-Allwright when stocking grows past 30 pharmacies. Right scenario: Phase 3, paired with HubSpot Pharmacy custom object.
Highest pure wow factor. Wave A unlocked port-readiness: truPRO + truME architecture maps cleanly onto MCAP, FHIR-compliant export 80%+ overlap with HPRA pharmacovigilance. Why not first: it pulls focus to truMED on a call that is supposed to be about Oleo's monopoly window, and "his to keep" is partial because the architecture is borrowed. What would change our mind: if Richard pivots the conversation to truMED. Right scenario: the Cross-Property Cascade hybrid.
Tactical companion to W9. Reason it scores 13 and is not the headline: it is execution, not strategy. 5 ready-to-send outreach drafts to Catherine Reilly, Catherine Shanahan, Martin Wall, Damien O'Reilly, Daniel McConnell. What would change our mind: if Richard says "we just need press right now". Right scenario: Tomas + John send these the week W1 ships, so press lands in the same news cycle as the readiness package.
Compounds while Olio.com is parked. Adds a 3rd anchor to Richard's Wikipedia notability case (entrepreneur-with-multiple-companies is harder to delete than single-company). The catch: it pays off in 12-24 months, not on Tuesday. What would change our mind: if Richard signals Olio.com is unparking sooner than expected. Right scenario: a quiet Phase 1 add-on inside the Cross-Property Cascade hybrid.
The retest of the 200-cell matrix at weeks 4, 12, and 24. Tracks the floor lift from 11 percent toward 19-23 percent. Reason it is not lead: it is a measurement asset, not a delivery asset. Rule 05 framing: increased likelihood of citation, never guaranteed. What would change our mind: if Richard wants explicit before-and-after proof. Right scenario: retainer Phase 1 reporting spine, not the wedge entry.
Only Irish MCAP voice producing one. 4-page exec summary + 12-page evidence appendix + 1-page Oleo positioning + meeting-request letter template. Reason it is not the headline: Allwright report-out is the immediate trigger; Oireachtas legislative debate sits downstream of report-out. What would change our mind: if Richard names a specific TD or Senator he is engaging. Right scenario: the Pre-Allwright Stack hybrid.
If Tomas + John see the menu, they will combine. Below are the six hybrids worth pre-naming. Each has a cost, a time-to-ship, the signal it sends, and the room-temperature it wins in.
= W3 + W9 + W2 + W16 · submission landing page + press kit + 22-consultant map + Oireachtas briefing pack
Cost: Free · Time: 7 days · Signals: we are the public regulatory voice for Oleo into the Allwright Review and the legislative debate that follows.
Wins in the room when Richard mentions the Allwright submission, journalists chasing him for quotes, the Oireachtas Health Committee, or names a specific TD. This is the "we draft, you sign, you become the named industry voice on the record" stack.
= W4 + W6 + W14 · condition navigator + Medical Cannabis ID Card brand-claim + Olio entity layer
Cost: under EUR 1k · Time: 10 days · Signals: patient-side fluency, ASAI-compliant patient surfaces, future-Olio readiness baked in.
Wins in the room when Richard frames patient discovery as the bottleneck or mentions Olio.com B2C ambitions in the same breath as Oleo. Pulls in real Reddit verbatims (Stewart + Sarah McKeown, the McKeown story, r/MedicalCannabis_NI canonical hub run by u/markoj22) as evidence framing.
= W2 + W10 + W13 · consultant map + CME-CPD accredited series + 5-outlet pre-pitch package
Cost: EUR 1-5k · Time: 18 days · Signals: we own the prescriber-side moat end to end, accredited content travels through formal CPD infrastructure.
Wins in the room when Richard says "the consultants are the constraint" or names specific specialties (neurology, oncology, palliative). Personas-v1.md persona 5 hypothesised voice plays directly into this stack: "the paperwork is a tax on a clinic I am already running over".
= W1 + W7 + W11 · readiness package + HPRA pharmacovigilance AI + pharmacy locator skeleton
Cost: under EUR 2k · Time: 14 days · Signals: we remove the operational ceiling, not just the marketing one.
Wins in the room when Richard or Shirley names ops headcount, regulatory paperwork, or pharmacy supply as the binding constraint. The HPRA AI is the highest-leverage internal hire Oleo can make without growing headcount.
= W12 + W14 + Budtender Brain demo · truMED bot pattern port + Olio entity layer + visible Budtender result
Cost: under EUR 1k · Time: 9 days · Signals: we run all three of Richard's properties under one architecture without breaking the ASAI 7th edition cross-property risk.
Wins in the room when the Budtender call has gone well and Richard pivots to "what about the others?" This is the Tuesday "by the way" upgrade path. Business-family-map.md confirms the architectural rehearsal is real (truPRO + truME directly maps).
= W1 + W2 + W7 + W13 · readiness package + standalone consultant map + HPRA AI + ready-to-send press
Cost: under EUR 1k · Time: 14 days · Signals: we are not pitching - we are already running the play.
Wins in the room when Richard reads as decisive and budget is not the constraint. Save for Tue 20 May close. Adds W7's operational wow on top of W1's strategic wow, with W13's press execution landing the same news cycle. Highest defensible scope expansion.
Position the wedge as the cost of NOT being ready. Allwright will report Q2-Q3 2026; the question is whether Oleo or Tilray claims the AI citation slots and prescriber attention on day one. The deep audit shows Allwright Review queries at 0 cells across all 4 engines today. The Readiness Package is insurance against being second.
Lean into Richard's medtech instinct. We work in his colours, on his domains, no agency logo on anything. He ships the wins to his board. The agency is invisible by design, which is exactly how a regulated medical brand wants its marketing infrastructure delivered. Per STYLE-GUIDE section 15: would Richard hand this across the table at HPRA without flinching?
truMED is the architecture. Oleo is the regulated medical instance of that architecture. We are the bridge that ports the pattern. Wave A confirmed truPRO + truME maps directly: provider data export (FHIR-compliant), patient education layer, adverse event capture. This frames us as the only agency that can make Richard's portfolio compound across all three properties without breaking ASAI.
We are not pitching marketing. We are pitching a co-author for the regulatory submission and the Oireachtas briefing. The Allwright submission needs an evidence pack with patient outcomes, supply readiness, prescriber capability. We draft it. Richard signs. He becomes the named industry voice in the review record. The Oireachtas pack (W16) extends that voice into the legislative debate.
Wins on Oleo compound onto Budtender (consumer credibility from medical-grade brand) and onto truMED (operational pattern validated in a regulated context). Three properties, one agency, one architecture, three sets of wins. Business-family-map.md section 3 names the compounding logic: the stack is the moat, not any single node.
Use this if Richard surfaces specific signals during the Tuesday "by the way" moment or on the close call. Each branch maps a verbal cue to a concrete next step. Every branch terminates at a wedge or hybrid name.
| If Richard says... | Then ship... | Why |
|---|---|---|
| "Allwright" or mentions the submission | W3 - Allwright Submission Landing Page within 48 hours | The fastest visible regulatory signal we can put on his domain. AI deep audit floor is 0 cells today; W3 lifts it to 6 in 2-3 days. Frees him to forward the link to journalists same week. |
| "Budget is tight pre-Allwright" or "wait until expansion" | W2 - 22-Consultant Re-Activation Map alone, 3 days, free | Free, ships fast, is the asset he uses today and on Allwright morning. Removes the budget objection while landing the highest-scoring standalone wedge (14/20). |
| "OleoCare data" or "Shirley is working on the app" | W7 - HPRA Pharmacovigilance AI prototype | Operational signal, talks Shirley's language, demonstrates we read the architecture not just the marketing. Pairs with W12 truMED port if she opens that door. |
| "UK clinics" or "Belfast" or "cross-border" | W8 - Curaleaf Belfast vs Oleo comparison page | Captures the existing leak, ASAI-safe pathway content, ranks for the cross-border search intent. Active legal frame: ROI cross-border transport is a Misuse of Drugs offence today. |
| "Wait for Allwright before doing anything" | W14 - Olio.com entity layer in parallel | Quiet entity build that costs nothing now and is ready when Olio.com unparks. Adds 3rd anchor to Wikipedia notability. Lets us stay close without committing scope. |
| "What about the consultants?" or names a specialty | The Prescriber Stack hybrid (W2 + W10 + W13) | 22-to-50 consultant expansion is the single biggest pre-Allwright lever. Accredited content travels through CPD infrastructure, ready-to-send press lands the same news cycle. |
| "Bedrocan" or asks about supply | W5 - Bedrocan Trust Page standalone, 3 days, free | Surfaces the most under-leveraged credential Oleo owns. November 2021 announcement quoted in the second paragraph, schema.org partnerOf, NL magistral pipeline diagrammed. |
| "Press" or names a journalist | W13 - 5-Outlet Pre-Pitch Package within 48 hours | Catherine Reilly is the dual-path slot (IMT + Medical Independent). Five drafts ready. Tomas + John edit and send same day. |
| "Oireachtas" or names a TD/Senator | W16 - Oireachtas Health Committee Briefing Pack | 4-page exec summary + 12-page evidence appendix + meeting-request letter template. Only Irish MCAP voice producing one. Lobbying Act 2015 transparent by design. |
| "What about Panacea? EU sales?" | Panacea MDR Class IIa scoping conversation (out of W-set) | Outside core OO scope but referrable. Showing we know the MDR pathway separates us from generic agencies. Refer to a regulatory partner; OO co-delivers content on confirmation. |
| "What about Budtender too?" (Tuesday upgrade signal) | The Cross-Property Cascade hybrid (W12 + W14 + Budtender Brain demo) | Richard is opening the door to multi-property scope. Show the architecture that makes all three compound while the ASAI walls hold by design. |
| "What does the close pricing look like?" (Tue 20 May) | The Big Dawg Wedge (W1 + W2 + W7 + W13) | The full operational + regulatory + press wow. This is the upward-scope move. 14 days to ship, under EUR 1k cost, four wedges combining for maximum signal. |
Day-by-day plan to deliver the locked W1 Regulatory Readiness Package. Every day has a single deliverable, an owner, and an acceptance check before the next day starts.
| Risk | Mitigation |
|---|---|
| 22-consultant data sourcing too slow on Day 2 | Phase 1 = public registers + LinkedIn + Trinity 2025 survey. Hospital + specialty must have. Last-known volume can ship as "unknown" and backfill in week 2. |
| ASAI flagging on Day 5 forces rewrite | Day 5 budgets 50 percent rewrite buffer; if more than 3 pages flag, Day 6 absorbs the slip and Day 7 walkthrough holds. |
| Shirley unavailable for OleoCare audit sign-off | Audit ships independently with explicit "pending Shirley sign-off" caveat. Does not block walkthrough. |
| Richard cancels the Day 7 call | Rebook within 5 days. Staging stays live, all assets remain his to keep. W13 press package goes out anyway if he green-lights by email. |
| Bedrocan partnership copy overstates the relationship | STYLE-GUIDE section 9 governs. Factual provenance only, no co-branded promotion. Shirley reviews every line that touches Bedrocan. |
| 22-consultant map names a consultant who has not consented | Phase 1 ships as internal-only OO research artefact. Consent-gated public-facing version follows in Phase 2 retainer. |
Wedge Vault: Oleo Technologies · v2.0 · 2026-05-08 · Internal only · Tomas + John + Donal · Wave A refresh